Want to see NVS full AI Analyst Report?
NVS Stock Chart & Stats
$159.98
-$1.13(-0.72%)
At close: 4:00 PM EDT
$159.98
-$1.13(-0.72%)
Day’s Range― - ―
52-Week Range$121.57 - $170.46
Previous CloseN/A
Volume1.83M
Average Volume (3M)2.16M
Market Cap
$275.30B
Enterprise Value$341.69B
Total Cash (Recent Filing)$7.69B
Total Debt (Recent Filing)$49.01B
Price to Earnings (P/E)22.8
Beta0.26
Next Earnings
Oct 27, 2026EPS Estimate
2.27Next Dividend Ex-DateN/A
Dividend Yield3.16%
Share Statistics
EPS (TTM)6.66
Shares Outstanding2,034,819,500
10 Day Avg. Volume1,664,729
30 Day Avg. Volume2,163,576
Financial Highlights & Ratios
PEG Ratio0.85
Price to Book (P/B)5.79
Price to Sales (P/S)4.88
P/FCF Ratio15.11
Enterprise Value/Market Cap1.24
Enterprise Value/Revenue6.14
Enterprise Value/Gross Profit8.25
Enterprise Value/Ebitda15.35
Forecast
1Y Price Target
$159.00Price Target Upside-0.61% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)8.81
Revenue Forecast (FY)$57.25B
Bulls Say, Bears Say
Bulls Say
Strong Profitability And Cash GenerationHigh margins indicate substantial economic value from Novartis’s prescription-medicine portfolio, while robust free cash flow supports research investment, acquisitions, dividends, and buybacks. Cash flow close to earnings also suggests that reported profitability is generally supported by cash generation.
Priority Brands Provide Broad Growth MomentumGrowth across several priority brands reduces reliance on a single product and demonstrates commercial traction in oncology, cardiovascular disease, immunology, and neuroscience. Broad adoption can help offset mature-product erosion and support portfolio growth over the next several quarters.
Positive Remibrutinib Phase III DataPositive Phase III results strengthen Novartis’s multiple-sclerosis franchise with a potential differentiated oral therapy showing efficacy and a favorable safety profile. Successful filings and approvals could expand the company’s neurology platform and add another durable growth contributor.
Bears Say
Generic Erosion Is Pressuring Sales And EarningsGeneric competition is reducing the contribution from established products, creating a continuing headwind to revenue and operating income. This raises the burden on newer launches to replace lost sales and may keep margins under pressure as the portfolio mix changes.
Higher Leverage Reduces Financial FlexibilityThe sharp increase in debt makes Novartis more sensitive to business volatility and financing costs, while limiting flexibility for additional investment or acquisitions. Although the company retains substantial equity and assets, higher leverage increases obligations against future cash flows.
Clinical Setbacks Increase Pipeline RiskFailure on a pivotal endpoint weakens the near-term outlook for del-desiran and highlights the uncertainty inherent in Novartis’s neuromuscular pipeline. Further regulatory discussions may be required, while additional programs must deliver to sustain broader pipeline expectations.
Novartis News
NVS FAQ
What was Novartis Ag’s price range in the past 12 months?
Novartis Ag lowest stock price was $121.57 and its highest was $170.46 in the past 12 months.
What is Novartis Ag’s market cap?
Novartis Ag’s market cap is $275.30B.
When is Novartis Ag’s upcoming earnings report date?
Novartis Ag’s upcoming earnings report date is Oct 27, 2026 which is in 7 days.
How were Novartis Ag’s earnings last quarter?
Novartis Ag released its earnings results on Jul 21, 2026. The company reported $2.41 earnings per share for the quarter, beating the consensus estimate of $2.172 by $0.238.
Is Novartis Ag overvalued?
According to Wall Street analysts Novartis Ag’s price is currently Overvalued.
Does Novartis Ag pay dividends?
Novartis Ag pays a Annually dividend of $4.74 which represents an annual dividend yield of 3.16%. See more information on Novartis Ag dividends here
What is Novartis Ag’s EPS estimate?
Novartis Ag’s EPS estimate is 2.27.
How many shares outstanding does Novartis Ag have?
Novartis Ag has 2,034,819,500 shares outstanding.
What happened to Novartis Ag’s price movement after its last earnings report?
Novartis Ag reported an EPS of $2.41 in its last earnings report, beating expectations of $2.172. Following the earnings report the stock price went up 2.882%.
Which hedge fund is a major shareholder of Novartis Ag?
Currently, no hedge funds are holding shares in NVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novartis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$159.00 (-0.61% Downside)
$159.00 (-0.61% Downside)
Blogger Sentiment
Bullish
NVS Sentiment 67%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 5.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 0.1%
Last 30 Days ▼ 0.1%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Negative
20 days / 200 days
Momentum
16.51%
12-Months-Change
Fundamentals
Return on Equity
29.64%
Trailing 12-Months
Asset Growth
16.90%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Novartis Ag
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
NVS Company Deck
NVS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely positive commercial and pipeline picture: multiple priority brands delivered high double-digit growth, Q2 returned to net sales growth, important regulatory and biomarker milestones were achieved, and management reaffirmed full-year guidance while outlining a busy H2 of pivotal readouts. Offsetting risks include H1 generic erosion and margin pressure (partly acquisition-related), temporary phasing effects that favor Q2, and several high-impact clinical readouts and regional competitive pressures that remain uncertain. On balance, the upside from strong product momentum, cash generation and pipeline progress outweighs the near-term headwinds.View all NVS earnings summariesNVS Stock 12 Month Forecast
Average Price Target
$159.00
▼(-0.61% Downside)
Technical Analysis
Ownership Overview
―
Insiders
1.38% Mutual Funds
0.12% Other Institutional Investors
98.13% Public Companies and Individual Investors